247 related articles for article (PubMed ID: 22799876)
21. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M
Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787
[TBL] [Abstract][Full Text] [Related]
22. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.
Cadier B; Durand-Zaleski I; Thomas D; Chevreul K
PLoS One; 2016; 11(2):e0148750. PubMed ID: 26909802
[TBL] [Abstract][Full Text] [Related]
23. A Cost-Effectiveness Analysis of Smoking-Cessation Interventions Prior to Posterolateral Lumbar Fusion.
Zhuang T; Ku S; Shapiro LM; Hu SS; Cabell A; Kamal RN
J Bone Joint Surg Am; 2020 Dec; 102(23):2032-2042. PubMed ID: 33038088
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
[TBL] [Abstract][Full Text] [Related]
25. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children.
Johansson PM; Tillgren PE; Guldbrandsson KA; Lindholm LA
Scand J Public Health; 2005; 33(5):343-52. PubMed ID: 16265801
[TBL] [Abstract][Full Text] [Related]
26. Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis.
Jordan RE; Majothi S; Heneghan NR; Blissett DB; Riley RD; Sitch AJ; Price MJ; Bates EJ; Turner AM; Bayliss S; Moore D; Singh S; Adab P; Fitzmaurice DA; Jowett S; Jolly K
Health Technol Assess; 2015 May; 19(36):1-516. PubMed ID: 25980984
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.
Hoogendoorn M; Feenstra TL; Asukai Y; Borg S; Hansen RN; Jansson SA; Samyshkin Y; Wacker M; Briggs AH; Lloyd A; Sullivan SD; Rutten-van Mölken MP
Value Health; 2014 Jul; 17(5):525-36. PubMed ID: 25128045
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program.
Bourbeau J; Granados D; Roze S; Durand-Zaleski I; Casan P; Köhler D; Tognella S; Viejo JL; Dal Negro RW; Kessler R
Int J Chron Obstruct Pulmon Dis; 2019; 14():645-657. PubMed ID: 30936689
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of a brief counselling for smoking cessation in dentistry: a case study comparing two health economic models.
Virtanen SE; Galanti MR; Johansson PM; Feldman I
BMJ Open; 2017 Jul; 7(7):e016375. PubMed ID: 28729321
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of integrated COPD care: the RECODE cluster randomised trial.
Boland MR; Kruis AL; Tsiachristas A; Assendelft WJ; Gussekloo J; Blom CM; Chavannes NH; Rutten-van Mölken MP
BMJ Open; 2015 Nov; 5(10):e007284. PubMed ID: 26525419
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of the Aerobika* oscillating positive expiratory pressure device in the management of COPD exacerbations.
Khoudigian-Sinani S; Kowal S; Suggett JA; Coppolo DP
Int J Chron Obstruct Pulmon Dis; 2017; 12():3065-3073. PubMed ID: 29089755
[TBL] [Abstract][Full Text] [Related]
34. Projecting Long-term Health and Economic Burden of COPD in the United States.
Zafari Z; Li S; Eakin MN; Bellanger M; Reed RM
Chest; 2021 Apr; 159(4):1400-1410. PubMed ID: 33011203
[TBL] [Abstract][Full Text] [Related]
35. Translating Pharmacometrics to a Pharmacoeconomic Model of COPD.
Slejko JF; Willke RJ; Ribbing J; Milligan P
Value Health; 2016 Dec; 19(8):1026-1032. PubMed ID: 27987629
[TBL] [Abstract][Full Text] [Related]
36. Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective.
Cedillo S; Sicras-Mainar A; Jiménez-Ruiz CA; Fernández de Bobadilla J; Rejas-Gutiérrez J
Eur Addict Res; 2017; 23(1):7-18. PubMed ID: 27794567
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity.
Sin DD; Golmohammadi K; Jacobs P
Am J Med; 2004 Mar; 116(5):325-31. PubMed ID: 14984818
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of enhancing a Quit-and-Win smoking cessation program for college students.
Popp J; Nyman JA; Luo X; Bengtson J; Lust K; An L; Ahluwalia JS; Thomas JL
Eur J Health Econ; 2018 Dec; 19(9):1319-1333. PubMed ID: 29687268
[TBL] [Abstract][Full Text] [Related]
40. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
Thavorn K; Chaiyakunapruk N
Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
